PipeBio ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.2% 1.2% 1.2% 1.2% 1.2%  
Bankruptcy risk  0.0% 17.8% 21.5% 17.2% 20.3%  
Credit score (0-100)  0 8 4 9 4  
Credit rating  N/A B B BB B  
Credit limit (kDKK)  0.0 0.0 -0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 979 -186 349 559  
EBITDA  0.0 -15.0 -2,435 -3,045 -3,264  
EBIT  0.0 -15.0 -2,435 -3,045 -3,264  
Pre-tax profit (PTP)  0.0 -17.0 -2,441.7 -3,197.5 -3,574.5  
Net earnings  0.0 45.0 -2,441.7 -2,671.3 -2,773.5  
Pre-tax profit without non-rec. items  0.0 -17.0 -2,442 -3,198 -3,575  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 85.0 -2,356 -5,028 -7,801  
Interest-bearing liabilities  0.0 1.0 2,502 5,486 6,194  
Balance sheet total (assets)  0.0 543 699 2,466 4,271  

Net Debt  0.0 -459 1,949 4,709 4,889  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 979 -186 349 559  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 59.9%  
Employees  0 2 0 4 5  
Employee growth %  0.0% 0.0% -100.0% 0.0% 25.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 543 699 2,466 4,271  
Balance sheet change%  0.0% 0.0% 28.8% 252.6% 73.2%  
Added value  0.0 -15.0 -2,435.4 -3,045.4 -3,264.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 -1.0 -2.0 -3.0 -4.0  

Profitability 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% -1.5% 1,312.2% -871.4% -584.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% -2.8% -135.3% -57.7% -32.7%  
ROI %  0.0% -17.4% -188.2% -76.2% -54.8%  
ROE %  0.0% 52.9% -622.6% -168.8% -82.3%  

Solidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 15.7% -77.1% -67.1% -64.6%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 3,060.0% -80.0% -154.6% -149.8%  
Gearing %  0.0% 1.2% -106.2% -109.1% -79.4%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 400.0% 0.5% 3.8% 6.4%  

Liquidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 1.2 0.2 0.3 0.4  
Current Ratio  0.0 1.2 0.2 0.3 0.4  
Cash and cash equivalent  0.0 460.0 553.6 777.1 1,304.7  

Capital use efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 85.0 -2,356.4 -5,027.7 -7,801.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 -8 0 -761 -653  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 -8 0 -761 -653  
EBIT / employee  0 -8 0 -761 -653  
Net earnings / employee  0 23 0 -668 -555